Q1 Earnings Forecast for DYAI Issued By HC Wainwright

Dyadic International Inc. (NASDAQ:DYAI) – Research analysts at HC Wainwright issued their Q1 2026 earnings per share (EPS) estimates for Dyadic International in a report issued on Thursday, October 23rd. HC Wainwright analyst S. Ramakanth anticipates that the biotechnology company will post earnings of $0.03 per share for the quarter. HC Wainwright has a “Buy” rating and a $3.00 price objective on the stock. The consensus estimate for Dyadic International’s current full-year earnings is ($0.18) per share. HC Wainwright also issued estimates for Dyadic International’s Q2 2026 earnings at ($0.05) EPS, Q3 2026 earnings at $0.04 EPS, Q4 2026 earnings at ($0.04) EPS, FY2028 earnings at $0.24 EPS and FY2029 earnings at $0.24 EPS.

Dyadic International (NASDAQ:DYAI) last issued its earnings results on Wednesday, August 13th. The biotechnology company reported ($0.06) EPS for the quarter, meeting analysts’ consensus estimates of ($0.06). Dyadic International had a negative return on equity of 355.39% and a negative net margin of 134.84%.The company had revenue of $0.97 million during the quarter, compared to the consensus estimate of $0.60 million.

Other equities analysts also recently issued reports about the company. Weiss Ratings restated a “sell (d-)” rating on shares of Dyadic International in a research note on Wednesday, October 8th. Craig Hallum assumed coverage on Dyadic International in a research note on Monday, September 8th. They issued a “buy” rating for the company. Two research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $3.00.

Dyadic International Stock Performance

Shares of DYAI stock opened at $1.18 on Friday. The company has a quick ratio of 2.02, a current ratio of 2.02 and a debt-to-equity ratio of 5.40. The business has a 50 day moving average of $1.02 and a two-hundred day moving average of $1.04. Dyadic International has a 52 week low of $0.71 and a 52 week high of $2.20. The company has a market cap of $42.70 million, a P/E ratio of -6.21 and a beta of 1.00.

Institutional Investors Weigh In On Dyadic International

A number of hedge funds have recently made changes to their positions in DYAI. Bank of America Corp DE raised its holdings in shares of Dyadic International by 16,146.7% during the fourth quarter. Bank of America Corp DE now owns 27,132 shares of the biotechnology company’s stock valued at $47,000 after buying an additional 26,965 shares during the last quarter. Callan Capital LLC raised its holdings in shares of Dyadic International by 86.8% during the first quarter. Callan Capital LLC now owns 50,759 shares of the biotechnology company’s stock valued at $69,000 after buying an additional 23,585 shares during the last quarter. Chapin Davis Inc. raised its holdings in shares of Dyadic International by 4.7% during the second quarter. Chapin Davis Inc. now owns 882,849 shares of the biotechnology company’s stock valued at $874,000 after buying an additional 40,000 shares during the last quarter. Finally, AlphaCore Capital LLC bought a new stake in shares of Dyadic International during the second quarter valued at approximately $50,000. Institutional investors own 27.95% of the company’s stock.

Dyadic International Company Profile

Dyadic International, Inc, a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States and internationally. It utilizes C1-cell protein production platform based on an industrially proven microorganism (C1) for the development and production of biologic products including enzymes and other proteins for human and animal health.